• Home
  • Search Results
  • Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs.

Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs.

Expert opinion on investigational drugs (2014-04-29)
Luca Semerano, Allan Thiolat, Emeline Minichiello, Gaëlle Clavel, Natacha Bessis, Marie-Christophe Boissier
ABSTRACT

IL-6 is a key cytokine in the pathogenesis of rheumatoid arthritis (RA). The clinical efficacy of tocilizumab (TCZ), a humanized anti-IL6-receptor mAb, confirmed the value of IL-6 blockade in this disease. A number of new anti-IL-6 biologics are currently in Phase I - III of clinical development for RA. This article reviews the available results from Phase II trials of investigational anti-IL-6 agents in RA. The authors discuss the potential relevance of alternative IL-6-blocking agents, with regard to their specific molecular targets in IL-6 signaling pathways and to the main open questions in the clinical research agenda for anti-IL-6 biologics. The results of Phase II trials of new anti-IL-6 biologics show promising results in terms of efficacy. The most frequently reported adverse events were not unexpected based on previous experience with TCZ. Further evidence is needed to appraise whether the difference in molecular structure or in the specific target of new anti-IL-6 biologics might result in added therapeutic value over TCZ. New data from Phase III trials that provides a head-to-head comparison against TCZ and anti-TNF agents with or without methotrexate background treatment are expected in the future.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Graphene ink in water, inkjet printable
Sigma-Aldrich
Anti-IL6 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
Anti-IL6 high affinity antibody, Mouse monoclonal, clone IL6-2A3, purified from hybridoma cell culture
Sigma-Aldrich
Anti-IL6 high affinity antibody, Mouse monoclonal, clone IL6-4G1, purified from hybridoma cell culture
Sigma-Aldrich
SILuRich Anti-IL6 MAb, biotin conjugated, clone IL6-4G1, purified from hybridoma cell culture

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.